Evidence map›Paper›PMID 41757889›Full record

ArticleJournal of bacteriology2026

Bassam El Hafi, Fabrice Jean-Pierre, Lily Taub, Thomas H Hampton, George A O'Toole

Abstract read
In one paragraph

Article in Journal of bacteriology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bassam El HafiDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.ORCID 0000-0003-3277-2948
Fabrice Jean-PierreDépartement de Biologie, Université de Sherbrooke, Sherbrooke, Québec, Canada.ORCID 0000-0002-3056-8356
Lily TaubDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.ORCID 0009-0008-6625-6216
Thomas H HamptonDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.ORCID 0000-0003-0543-402X
George A O'TooleDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.ORCID 0000-0002-2861-4392

Funding

Metabolic Basis of Bacterial Community Function in the Cystic Fibrosis AirwayR01AI155424 · NIAID · DARTMOUTH COLLEGE · PI O'TOOLE, GEORGE A. · 2021 to 2025
$2.3M
NIAID NIH HHS R01 AI155424
6 · The paper itself

Abstract

The latest generation of cystic fibrosis transmembrane conductance regulator-targeted modulator therapy, Elexacaftor/Tezacaftor/Ivacaftor (ETI), has significantly improved the clinical outcomes of persons with cystic fibrosis (pwCF) but does not appear to completely eliminate CF respiratory microbial colonization. Here, we analyzed over 4,200 publicly available respiratory microbiomes spanning pre- and post-ETI treatment periods and further stratified by age and type of sample. Our analyses reveal that despite reshaping of community composition by ETI, classical CF pathogens such as

Indexed as

AntibiosisCystic FibrosisMicrobiotaPrevotella melaninogenicaRespiratory SystemStreptococcusHumansSputumcystic fibrosismicrobiomenitric oxidepolymicrobialPrevotellaPseudomonasStreptococcus

Identifiers

PMID41757889
PMCPMC13001228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.